Selecta Biosciences (Watertown, MA) a clinical-stage biopharmaceutical company focused on a new class of vaccines and immunotherapies for nicotine addiction, cancer, diabetes, influenza and human papilloma virus (HPV) closed a $47.25M Series D financing. Participants include Rusnano.